453
Views
30
CrossRef citations to date
0
Altmetric
Original Article

Adherence and persistence in patients with severe osteoporosis treated with teriparatide

, , , , , & show all
Pages 675-681 | Accepted 08 Dec 2009, Published online: 15 Jan 2010
 

Abstract

Introduction:

Medical intervention plays a key role in the treatment of postmenopausal osteoporosis and patients’ adherence to therapy is essential for optimal clinical outcomes. While adherence in RCTs is usually around 70–90%, a previous study showed that in clinical practice only 27.8% and 46.5% of the women on oral daily vs. weekly alendronate were still on treatment after 12 months. Data on adherence to teriparatide (TPTD) treatment of severe postmenopausal osteoporosis are available from only few countries. This study assessed adherence and persistence with TPTD in Germany.

Material and methods:

A sample of 50 women with severe postmenopausal osteoporosis treated with TPTD in accordance to the German osteoporosis guidelines was included. Treatment was initiated 12–24 months before recruitment. Patient self report was assessed using a validated questionnaire. In addition medication possession ratio (MPR) was calculated by counting prescription refills, and therefore all physicians who were treating the patients for any disease were contacted. Patients were classified adherent at 12 months of therapy if self-reported adherence and an MPR of ≥80% were achieved. Persistence was calculated in months and analysed with a Kaplan–Meier estimate.

Results:

Apart from a significantly lower age at menopause in the adherent group (46.1 vs. 50.0; p < 0.006) there were no significant differences in baseline demographics between adherent and non-adherent patients. After 12 months, 80% of the patients treated with TPTD were adherent, while 20% were non-adherent. A significant correlation with treatment adherence was found for self-reported medication tolerability (p < 0.001). Furthermore 79% of patients were persistent after 12 months.

Conclusion:

These results indicate that more patients seem to be adherent and persistent with TPTD than with oral treatments of postmenopausal osteoporosis. As these patients suffered from severe osteoporosis and sustained several fragility fractures, the generalisability of our retrospective study analysing a small sample is limited. The major factor that reduced adherence and persistence was tolerability. These findings are of practical relevance as numerous studies on antiresorptive therapies have shown that high adherence and persistence were needed to ensure an optimal therapeutic outcome.

Transparency

Declaration of funding

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Declaration of financial/other relationships

V.Z. has disclosed that he has served as a speaker for Eli Lilly, P&G, Novartis, Daiichi Sankyo and Sanofi Aventis. P.H. has disclosed that he has served as a speaker and consultant for Eli Lilly, P&G, Novartis, Daiichi Sankyo, GSK and Merck. The other authors have disclosed no relevant financial relationships.

Peer reviewers may receive honoraria from CMRO for their review work. Peer Reviewer 1 has disclosed that he/she is a shareholder in BMS. Peer Reviewer 2 has disclosed that he/she has no relevant financial interests.

Acknowledgements

The authors acknowledge the assistance of Olaf Hars, Berlin in the statistical analysis of this study and M. Koller, U.-S. Albert, A. Y. Nestoriuc and W. Rief in the design and validation process of the compliance questionnaire.

Parts of this work have been presented as a poster and within a working group presentation on adherence and persistence at the Annual Meeting of the ASBMR 2008, MontrealCitation28.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.